A population model of prostate cancer incidence.
Introduction of screening for prostate cancer using the prostate-specific antigen (PSA) marker of the disease led to remarkable dynamics of the incidence of the disease observed in the last two decades. A statistical model is used to provide a link between dissemination of PSA and the observed transient population responses. The model is used to estimate lead time, overdiagnosis and other relevant characteristics of prostate cancer screening.
Tsodikov
A
A
Department of Public Health Sciences, Division of Biostatistics, University of California Davis, One Shields Avenue, Davis, CA 95616, USA. atsodikov@ucdavis.edu
Szabo
A
A
Wegelin
J
J
D017668:Age of Onset; D000368:Aged; D001699:Biometry; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data; D008875:Middle Aged; D015233:Models, Statistical; D011153:Population; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology*; D018426:SEER Program; D013997:Time Factors; D014481:United States / Q000453:epidemiology
D017430:Prostate-Specific Antigen